Patents by Inventor Thomas Thum

Thomas Thum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LONG NON-CODING RNA AS THERAPEUTIC TARGET IN CARDIAC DISORDERS AND CARDIAC REGENERATION
    Publication number: 20230235403
    Abstract: The present invention relates to a long non-coding RNA as a therapeutic target in cardiac disorders.
    Type: Application
    Filed: July 28, 2021
    Publication date: July 27, 2023
    Applicant: Medizinische Hochschule Hannover
    Inventors: Thomas THUM, Huang CHENG-KAI, Christian BÄR
  • Viral vector particle based on AA V2 for gene therapy
    Publication number: 20230074198
    Abstract: The invention provides a viral vector particle based on AAV2, which in its capsid protein (CAP) contains an inserted amino acid section which confers tropism for cardiomyocytes.
    Type: Application
    Filed: February 22, 2021
    Publication date: March 9, 2023
    Inventors: Thomas Thum, Hildegard Büning, Laura Rode, Christian Bär
  • MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
    Publication number: 20230028937
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Application
    Filed: June 22, 2022
    Publication date: January 26, 2023
    Applicant: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20220348920
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: July 12, 2022
    Publication date: November 3, 2022
    Inventors: Thomas THUM, Kumarswamy REGALLA, Janika VIERECK
  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20220315924
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 6, 2022
    Inventors: Thomas THUM, Kumarswamy REGALLA, Janika VIERECK
  • IncRNAS for therapy and diagnosis of angiogenesis
    Patent number: 11459561
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 4, 2022
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Jan Fiedler
  • TREATMENT OF HEART FAILURE IN HUMAN SUBJECTS
    Publication number: 20220243204
    Abstract: The present invention refers to an oligonucleotide, which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders of a human subject.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 4, 2022
    Inventors: Thomas Thum, Claudia Ulbrich, Wilfried Hauke, Steffen Rump, Sandor Batkai
  • LncRNAs for therapy and diagnosis of cardiac hypertrophy
    Patent number: 11371043
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 28, 2022
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Kumarswamy Regalla, Janika Viereck
  • Compound for treatment of heart failure
    Publication number: 20220162597
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Application
    Filed: November 17, 2021
    Publication date: May 26, 2022
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos
  • Compound for treatment of heart failure
    Patent number: 11208651
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 28, 2021
    Assignee: Medizinische Hochschule Hannover
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos
  • LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
    Patent number: 11186838
    Abstract: The present invention relates to a compound inhibiting the expression and/or the activity of maternally expressed 3 (Meg3) for use in treating or preventing cardiac remodelling.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: November 30, 2021
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Maria-Teresa Piccoli, Janika Viereck, Shashi Kumar Gupta
  • Natural compounds and fibrosis
    Patent number: 11185539
    Abstract: The present invention relates to an inhibitor of miR-671-5p for use in a method of preventing or treating fibrosis. Further, the present invention encompasses a kit comprising said inhibitor of miR-671-5p. The present invention also relates to an in vitro method for identifying a compound for preventing or treating fibrosis.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 30, 2021
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER (MHH)
    Inventors: Thomas Thum, Katharina Schimmel, Quoc-Tuan Do, Philippe Bernard
  • Improved Compound for Treatment of Heart Failure
    Publication number: 20210180054
    Abstract: The present invention refers to an oligonucleotide which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 17, 2021
    Inventors: Thomas Thum, Sandor Batkai, Ariana Foinquinos
  • MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
    Publication number: 20210113603
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Application
    Filed: September 1, 2020
    Publication date: April 22, 2021
    Applicant: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY
    Publication number: 20200165604
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.
    Type: Application
    Filed: June 25, 2018
    Publication date: May 28, 2020
    Inventors: THOMAS THUM, KUMARSWAMY REGALLA, JANIKA VIERECK
  • Mitochondrial non-coding RNAs for predicting disease progression in heart failure and myocardial infarction patients
    Patent number: 10584383
    Abstract: The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 10, 2020
    Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE LILLE 2 (LILLE 2)—UNIVERSITY OF LAW AND HEALTH, CENTRE HOSPITALIER UNIVERSITAIRE LILLE (CHU), INSTITUT PASTEUR DE LILLE (IPL)
    Inventors: Thomas Thum, Regalla Kumarswamy, Florence Pinet, Christophe Bauters, Pascal De Groote
  • MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes
    Publication number: 20200069720
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Application
    Filed: August 16, 2019
    Publication date: March 5, 2020
    Applicant: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • IncRNAS FOR THERAPY AND DIAGNOSIS OF ANGIOGENESIS
    Publication number: 20190376061
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3.
    Type: Application
    Filed: January 15, 2019
    Publication date: December 12, 2019
    Inventors: Thomas THUM, Jan Fiedler
  • NATURAL COMPOUNDS AND FIBROSIS
    Publication number: 20190350923
    Abstract: The present invention relates to an inhibitor of miR-671-5p for use in a method of preventing or treating fibrosis. Further, the present invention encompasses a kit comprising said inhibitor of miR-671-5p. The present invention also relates to an in vitro method for identifying a compound for preventing or treating fibrosis.
    Type: Application
    Filed: January 29, 2018
    Publication date: November 21, 2019
    Inventors: Thomas Thum, Katharina Schimmel, Quoc-Tuan Do, Philippe Bernard
  • MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
    Patent number: 10434117
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 8, 2019
    Assignee: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross